Contact Us  +(1) 855 8KRANE8  info@kraneshares.com

KMED

KraneShares Emerging Market Healthcare Index ETF

Download KMED Presentation

Download Fact Sheet

Investment Strategy:

KMED seeks to provide investment results that, before fees and expenses, track the performance of the Solactive Emerging Markets Healthcare Index. The index seeks to track the equity market performance of companies engaged in the health care sector in various emerging markets. The issuers include small-cap, mid-cap, and large-cap companies involved in hospital management, healthcare management, pharmaceutical manufacturing, and biotechnology, among other sub-industries.

Emerging Market Healthcare Sector Highlights:

  • By 2040, emerging market countries on average are projected to increase healthcare spending as percent of GDP by 24.4% compared to just 9.8% in developed markets over the same time period1.
  • In emerging markets, rapid urbanization and rising income is fueling growth in the demand for healthcare services and treatments.
  • Healthcare now comprises the largest segment of household consumption in China2.
  • Cases of non-communicable diseases (NCDs) such as diabetes and cancer are rising steadily in emerging market countries, presenting a growth opportunity for innovators in the healthcare space.
  • Emerging markets governments are enacting policies such as India’s “National Health Protection Mission” and China’s “Healthy China 2030 Plan” to meet the growing demand for healthcare.

KMED features:

  • Exposure to the Emerging Market healthcare industry with a low correlation to US healthcare equities. Specifically: pharmaceuticals, biotechnology, healthcare administration services, and medical equipment.
  • Access to emerging market innovators in healthcare and pharmaceutical research.
  • Exposure to companies that benefit from the growing and aging EM populations.

1.) Dieleman, Joseph L et al., “Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries”, The Lancet , Volume 389 , Issue 10083 , 2005 - 2030.
2.) Data from the National Bureau of Statistics of China. Data as of 12/31/2017. Retrieved 6/30/2018.

Fund Details

Data as of 09/24/2018
TickerKMED
Primary ExchangeNYSE
CUSIP500767819
ISINUS5007678197
Net Assets$2,454,873
Total Annual Fund Operating Expense 0.79%
Inception Date8/29/18
Distribution FrequencySemiannually

Daily Performance

Data as of 09/24/2018
Premium Discount Chart
NAV
Net Asset Value$24.55 
Daily Change -0.62%
Price
Closing Price $24.42 
Daily Change-1.17%

Performance History

Distributions
Cumulative %
Data as of: 08/31/2018
Fund NAVClosing PriceIndex
1 Month
3 Month
6 Month
Since Inception0.56%0.40%
Cumulative %
Data as of quarter end: 06/30/2018
Fund NAVClosing PriceIndex
Since Inception

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Top 10 Holdings

Data as of 09/24/2018
Full Holdings .CSV
RankCompany Name% of Net AssetsTickerShares HeldMarket Value($)
1
SAMSUNG BIOLOGICS CO LTD
6.23%207940 KS322153,024
2
SUN PHARMACEUTICAL INDUS
5.58%SUNP IN15,940137,033
3
CELLTRION INC
5.48%068270 KS496134,535
4
JIANGSU HENGRUI MEDICINE
4.2%600276 CH11,600103,160
5
BANGKOK DUSIT MED SERVICE
3.6%BDMS TB113,60088,449
6
CELLTRION HEALTHCARE CO L
3.49%091990 KS1,02085,606
7
IHH HEALTHCARE BHD
3.16%IHH MK61,00077,561
8
KANGMEI PHARMACEUTICAL CO
2.71%600518 CH21,80066,398
9
CASH
2.37%58,05658,056
10
CIPLA LTD
2.14%CIPLA IN5,91852,637

Holdings are subject to change.